Caffeine, CYPA12 and Resistance Training

NCT06610123 | Completed

• 1 other identifier: CEIP/2024/2/037_2
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the prolonged effects of caffeine on this type of exercise. Objectives: The present study aims to analyze the prolonged effects of caffeine intake on neuromuscular adaptations to resistance training according to CYP1A2 polymorphism in men and women.

Conditions

CYP1A2 Polymorphism; Caffeine and Resistance Training

Outcome Measures

Primary Outcomes (9)

• Mean velocity at different %1RM

  Measuring bar mean velocity desplacement during bench press and back squat exercises.

  Through study completion, an average of 12 weeks

• Peak velocity at different %1RM

  Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.

  Through study completion, an average of 12 weeks

• Mean power output at different %1RM

  Measuring during bench press and back squat exercises.

  Through study completion, an average of 12 weeks

• Peak power output and time to reach peak power output at different %1RM

  Measuring during bench press and back squat exercises.

  Through study completion, an average of 12 weeks

• Number of repetitions performed at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 12 weeks

• Bar velocity deplacement performed in 1 set at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 12 weeks

• Power output generated in 1 set at 65%1RM until task failure

  In bench press and back squat exercise

  Through study completion, an average of 12 weeks

• Resting Metabolic Rate (RMR)

  Kcal at rest using a metabolic chart.

  Through study completion, an average of 12 weeks

• Maximal Fat Oxidation Rate (MFO)

  g/min (MFO) using a metabolic chart.

  Through study completion, an average of 12 weeks

Secondary Outcomes (6)

• Fat-free mass

  Through study completion, an average of 4 weeks

• Fat mass

  Through study completion, an average of 12 weeks

• Physical activity (METs-min/wk)

  Through study completion, an average of 12 weeks

• Dietary (g/kg of macronutrients)

  Through study completion, an average of 12 weeks

• Mood state

  Through study completion, an average of 12 weeks

Study Arms (8)

Genotype AA - Male - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine and Resistance training

Genotype AC or CC - Male - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine and Resistance training

Genotype AA - Male - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo and Resistance training

Genotype AC or CC - Male - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo and Resistance training

Genotype AA - Female - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine and Resistance training

Genotype AC or CC - Female - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine and Resistance training

Genotype AA - Female - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo and Resistance training

Genotype AC or CC - Female - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo and Resistance training

Interventions

Caffeine and Resistance training DIETARY_SUPPLEMENT

Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.

Genotype AA - Female - Caffeine; Genotype AA - Male - Caffeine; Genotype AC or CC - Female - Caffeine; Genotype AC or CC - Male - Caffeine

Placebo and Resistance training DIETARY_SUPPLEMENT

Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.

Genotype AA - Female - Placebo; Genotype AA - Male - Placebo; Genotype AC or CC - Female - Placebo; Genotype AC or CC - Male - Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age between ≥ 18 and ≤ 35 years.
• Body mass index (BMI) lowe than 25 kg/m².
• Physically active subjects (≥ 150 min/week of moderate exercise).
• Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
• Participants capable of performing the tests.

You may not qualify if:

• History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
• Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
• Body mass index (BMI) ≥ 25 kg/m².
• Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
• Performing strenuous exercise within 48 hours prior to the tests.
• Failing to replicate the same food intake on the two experimental days.
• Consuming caffeine after 6 PM on the day prior to training or testing.

Sponsors & Collaborators

• University of Alcala: lead

Study Sites (1)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Location

MeSH Terms

Interventions

Caffeine; Resistance Training

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Exercise Therapy; Rehabilitation; Aftercare; Continuity of Patient Care; Patient Care; Therapeutics; Physical Therapy Modalities; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Statistician
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 24, 2024
• Study Start: April 1, 2024
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: May 6, 2026

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will share

Locations

ES (1)